Hence, p53-deficient tumors may become strictly reliant on BID downstream of extra centrosomes for apoptosis induction and cancers that express BID variants with reduced cell-death activity and may develop rapid drug resistance (Flores‐Romero et al, 2022). Here, TP53 is linked to cancer.